AbbVie Stock Price, News & Analysis (NYSE:ABBV)

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie declared a -- dividend on Monday, September 9th. Shareholders of record on Tuesday, October 15th will be paid a dividend of $1.07 per share on Friday, November 15th. This represents a yield of 6.4%. The ex-dividend date is Friday, October 11th. View AbbVie's Dividend History.

AbbVie announced that its Board of Directors has authorized a share repurchase program on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board of directors believes its shares are undervalued.

AbbVie Inc (NYSE:ABBV) released its quarterly earnings results on Friday, July, 26th. The company reported $2.26 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.21 by $0.05. The business earned $8.26 billion during the quarter, compared to analysts' expectations of $8.09 billion. AbbVie had a net margin of 12.62% and a negative return on equity of 182.70%. The firm's revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.00 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

AbbVie issued an update on its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus estimate of $8.78.

14 analysts have issued 12-month target prices for AbbVie's stock. Their predictions range from $66.61 to $135.00. On average, they anticipate AbbVie's share price to reach $90.4675 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for AbbVie.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Media coverage about ABBV stock has been trending somewhat negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AbbVie earned a news impact score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for AbbVie.

AbbVie saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 51,014,000 shares, an increase of 11.2% from the July 31st total of 45,895,500 shares. Based on an average daily trading volume, of 10,600,000 shares, the short-interest ratio is currently 4.8 days. Approximately 3.5% of the company's stock are short sold. View AbbVie's Current Options Chain.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.22%), BlackRock Inc. (6.65%), BlackRock Inc. (6.65%), Northern Trust Corp (1.36%), Bank of New York Mellon Corp (1.07%) and Nuveen Asset Management LLC (0.65%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Parnassus Investments CA, Bank of Montreal Can, King Luther Capital Management Corp, Conning Inc. and First Trust Advisors LP. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., BlackRock Inc., Putnam Investments LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Man Group plc and Panagora Asset Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $72.39.

AbbVie has a market capitalization of $107.03 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.